As­traZeneca de­tails ‘very am­bi­tious’ strat­e­gy for ear­ly-stage obe­si­ty pro­grams

As­traZeneca plans to de­vel­op treat­ment op­tions for peo­ple with dif­fer­ent BMIs as part of its “very am­bi­tious” obe­si­ty strat­e­gy.

As­traZeneca CEO Pas­cal So­ri­ot on Thurs­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER